How Debiopharm’s Licensing Model Bridges The Biotech And Pharma Gap

 
• By Eliza Slawther
  
Antibody Drug Conjugate
Debiopharm is interested in licensing Antibody Drug Conjugate drugs for cancer • Source: Shutterstock

More from Global Vision

More from In Vivo